Neuroprotective effects of cyclosporine A deserve more study

Article

Cyclosporine A (CSA) protects retinal ganglion cells (RGCs) against glutamate-induced excitotoxicty and should be tested to see whether its neuroprotective properties will work against RGC disorders, researchers recently reported

Cyclosporine A (CSA) protects retinal ganglion cells (RGCs) against glutamate-induced excitotoxicty and should be tested to see whether its neuroprotective properties will work against RGC disorders, researchers writing in the Journal of Glaucoma say.

The investigators stressed RGC-5 cells with 10 mM glutamate for 24 hours, sometimes adding the immunosuppressive drug (1, 3, 6, or 9 μg/mL) to the medium. They used MTS assay to study cell viability and crystal violet staining to examine cell density, and used caspase 3/7 activity and Annexin V+/PI− flow cytometry to look at apoptosis induction.

They found that RGC-5 cells incubated with 10 mM glutamate for 24 hours had a 3.1-fold decrease in overall cell viability and a 3.4-fold decrease in cell density compared with controls. Adding 9 μg/mL of CSA to 10 mM glutamate caused a 2.7-fold increase in overall cell viability and a 2.5-fold increase in cell density compared with RGC-5 cells treated only with 10 mM glutamate. Also, it significantly reduced caspase 3/7 activity by 1.3-fold and the amount of Annexin V+/PI– cells by 2.8-fold compared with RGC-5 cells incubated with 10 mM glutamate by itself.

"The neuroprotective effect of CSA dose-dependently decreased with lower concentrations," the researchers wrote.

To read the abstract of the study, click here.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.